针对大脑的胰岛素信号,以对抗代谢障碍
Matthäus Metz1, Henning Fenselau2
1Synaptic Transmission in Energy Homeostasis Group, Max Planck Institute for Metabolism Research, Cologne, Germany; Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), University Hospital Cologne, Cologne, Germany; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Neuron
|January 8, 2026
概括
富利斯塔丁类1 (FSTL1) 被确定为一个关键的下丘脑胰岛素敏感剂. 准FSTL1可以减少体重增加和改善葡萄糖代谢,为肥胖和代谢障碍提供新的策略.
科学领域:
- 神经科学是一个神经科学.
- 代谢研究研究 代谢研究
- 内分泌学 在内分泌学.
背景情况:
- 肥胖和代谢障碍是全球重大健康挑战.
- 大脑的胰岛素信号在调节能量平衡和葡萄糖平衡中起着至关重要的作用.
- 确定治疗干预的新目标至关重要.
研究的目的:
- 为了研究利他类1 (FSTL1) 在下丘脑胰岛素敏感性中的作用.
- 评估药理学向FSTL1治疗肥胖和代谢功能障碍的潜力.
主要方法:
- 利用分子和生理技术来评估下丘脑中的FSTL1功能.
- 研究了FSTL1调节对体重,葡萄糖代谢和胰岛素信号通路的影响.
主要成果:
- 福利斯塔丁类1 (FSTL1) 被确定为下丘脑内胰岛素敏感性的关键调节器.
- 对FSTL1的药理向导致体重增加的显著减弱.
- 在FSTL1干预后观察到改善的全身葡萄糖代谢和胰岛素敏感性.
结论:
- FSTL1是一个关键的下丘脑胰岛素敏感剂,具有治疗潜力.
- 通过FSTL1向增强大脑胰岛素信号传递,为对抗肥胖提供了一个有希望的策略.
- 这项研究为管理代谢障碍开辟了新的途径.
相关概念视频
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581


